Memory Pharmaceuticals Corp.
This article was originally published in Start Up
Memory Pharmaceuticals intends to discover and develop drugs to treat mild-to-moderate dementia caused by disease, traumatic injury, or aging. Its technology is based on the work of Dr. Eric Kandel, one of the pioneers in discovering the molecular mechanisms of long-term memory formation.
You may also be interested in...
Drug development start-ups like Sention and David Pharmaceuticals are hoping to eliminate or reduce the safety risk inherent in drug development by identifying compounds Big Pharma has shelved or incorporated into marketed drugs and which are thought to be safe in humans. Instead of starting from scratch with de novo discovery of new molecules, they are focusing on in-licensing either promising compounds or marketed products that could benefit from incremental improvements.
With the limited success of traditional approaches to CNS, scientists are betting that genomics may hold the key to a new generation of drugs that stop disease progression and possibly reverse its impact. At least half a dozen companies focusing mostly on neurogenomics have started up and raised more than $100 million in the past three years. While they use standard genomics tools and follow typical post-genomics business models, they face special challenges due to the complexity of the brain.
In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)